Seeing as how you guys succeeded with the peptide delivery, perhaps you could find a way to make resveratrol orally "active". By now we all know that resverarol is one of the new kings of anti-aging and probably performance enhancement, but the problem is getting it in without injection. Resveratrol is so damn sensitive that most in typical supplement form is degraded and/or not absorbed.
Any thoughts on this, IBE?
There are a few Misunderstandings that we would like to address about Resveratrol.
1. Oral bioavailability isn't sufficient.
In Reality:
The extensive conjugation (sulfation and glucuronidation) doesn't mean that the compound has no oral bioavailability in humans. The question from those researching resveratrol has been how is resveratrol allowing for all of these beneficial effects despite having what they thought to be low oral bioavailability. One answer has been that perhaps, contrary
to the generalized rule of thumb that conjugation leads to inactivation, those
conjugated resveratrol metabolites were still somewhat active in serum. The
most recent answer with mounting evidence is that these conjugation products
are acting as reservoirs or endogenous/biologic pro-drugs in the body,
allowing for the release of free resveratrol locally and/or systemically after the
conjugation moieties (sulfate and Beta-glucuronic acid) are cleaved by
sulfatase and Beta-glucuronidase respectively (14-16). With this in mind, it explains
why a much lower amount of resveratrol than calculated (i.e., if we assume
conjugated products as permanently inactive metabolites) would need to be
administered in order to achieve necessary serum concentrations of the free
compound. A most recent study has in fact provided direct evidence to support this
hypothesis (17).
The fact that many who are actually providing original research are taking
regular trans-resveratrol provides some testament to the fact that oral
bioavailability isn't the issue it was once thought to be.
2. Insufficient stability and degradation of product.
In Reality:
The stability of resveratrol has only been shown to be an issue when one is
dealing with a reference standard of pure trans-resveratrol, not an extract
(18).
1. Wyke SM, Tisdale MJ. “Induction of protein degradation in skeletal muscle
by a phorbol ester involves upregulation of the ubiquitin-proteasome
proteolytic pathway.” 2006 May;78(25):2898-2910
2. Thaloor D, et al. “Systemic administration of the NF-kappaB inhibitor
curcumin stimulates muscle regeneration after traumatic injury.” Am J Physiol.
1999 Aug;277(2 Pt 1):C320-9
3. Tisdale MJ. “The ubiquitin-proteasome pathway as a therapeutic target for
muscle wasting.” J Support Oncol. 2005 May-Jun;3(3):209-17.
4. Wyke SM, Russell ST, Tisdale MJ. “Induction of proteasome expression in
skeletal muscle is attenuated by inhibitors of NF-kappaB activation.” Br J
Cancer. 2004 Nov 1;91(9):1742-50.
5. Juan ME, et al. “trans-Resveratrol, a natural antioxidant from grapes,
increases sperm output in healthy rats.” J Nutr. 2005 Apr;135(4):757-60.
6. Bowers JL, et al. “Resveratrol acts as a mixed agonist/antagonist for
estrogen receptors alpha and beta.” Endocrinology. 2000 Oct;141(10):3657-67.
7. Wang Y, et al. “The Red Wine Polyphenol Resveratrol Displays BI-Level
Inhibition on Aromatase in Breast Cancer Cells.” Toxicol Sci. 2006 Apr 11;
E-Published Ahead of Print
8. Turner RT, et al. “Is resveratrol an estrogen agonist in growing rats?”
Endocrinology. 1999 Jan;140(1):50-4.
9. Lu R, Serrero G. “Resveratrol, a natural product derived from grape,
exhibits antiestrogenic activity and inhibits the growth of human breast cancer
cells.” J Cell Physiol. 1999 Jun;179(3):297-304.
10. Bhat KP, Pezzuto JM. “Resveratrol exhibits cytostatic and antiestrogenic
properties with human endometrial adenocarcinoma (Ishikawa) cells.” Cancer
Res. 2001 Aug 15;61(16):6137-44.
11. Wu F, Safe S. "Differential activation of wild-type estrogen receptor
alpha and C-terminal deletion mutants by estrogens, antiestrogens and
xenoestrogens in breast cancer cells." J Steroid Biochem Mol Biol. 2007 Jan;103(1):1-9
12. Baur JA, Sinclair DA. “Therapeutic potential of resveratrol: the in
vivo evidence.” Nat Rev Drug Discov. 2006 Jun;5(6):493-506.
13. HemaIswarya S, Doble M. “Potential synergism of natural products in the
treatment of cancer.” Phytother Res. 2006 Apr;20(4):239-49.
14. Walle T, Hsieh F, DeLegge MH, Oatis JE Jr, Walle UK 2004 High
absorption but very low bioavailability of oral resveratrol in humans. Drug Metab
Dispos 32: 1377-1382
15. Wang LX, Heredia A, Song H, Zhang Z, Yu B, Davis C, Redfield R 2004
Resveratrol glucuronides as the metabolites of resveratrol in humans:
characterization, synthesis, and anti-HIV activity. J Pharm Sci 93:2448-2457.
16. Maier-Salamon A, Hagenauer B, Wirth M, Gabor F, Szekeres T, Jager W
2006 Increased Transport of Resveratrol Across Monolayers of the Human
Intestinal Caco-2 Cells is Mediated by Inhibition and Saturation of Metabolites.
Pharm Res 23:2107-2115
17. Abd El-Mohsen M, Bayele H, Kuhnle G, Gibson G, Debnam E, Kaila Srai
S, Rice-Evans C, Spencer JP 2006 Distribution of [3H]trans-resveratrol in rat
tissues following oral administration. Br J Nutr 96:62-70
